spironolactone has been researched along with avapro in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Schmidt, I | 1 |
| Ji, H; Li, X; Luo, W; Meng, Y; Wu, P; Xiao, B; Zhang, X; Zhang, Z | 1 |
| Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z | 1 |
| Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF | 1 |
| Rossignol, P; Zannad, F | 1 |
| Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC | 1 |
| Chen, X; Chen, Y; Li, Y; Liu, P; Wang, Y; Zhang, F | 1 |
| Anand, IS; Carson, PE; Desai, AS; Docherty, KF; Granger, CB; Jhund, PS; Komajda, M; McKelvie, RS; McMurray, JJV; Petrie, MC; Pfeffer, MA; Shen, L; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Briasouli, A; Briasoulis, A; Fujisaki, T; Kuno, T; Takagi, H; Ueyama, H | 1 |
| Aboul-Enein, HY; Ali, I; ALOthman, ZA; Alsheetan, KM | 1 |
| Anand, IS; Carson, P; Claggett, BL; Cunningham, JW; Desai, AS; Jhund, PS; John, JE; Kober, L; Lewis, EF; McMurray, JJV; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Yusuf, S; Zile, MR | 1 |
2 review(s) available for spironolactone and avapro
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Hospitalization; Humans; Irbesartan; Mineralocorticoid Receptor Antagonists; Mortality; Network Meta-Analysis; Perindopril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
5 trial(s) available for spironolactone and avapro
| Article | Year |
|---|---|
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chlorthalidone; Cross-Over Studies; Diuretics; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Insulin Resistance; Irbesartan; Male; Microelectrodes; Middle Aged; Spironolactone; Sympathetic Nervous System; Tetrazoles; Treatment Outcome | 2012 |
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
Topics: Adolescent; Adult; Aged; Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Bisoprolol; Blood Pressure; Blood Pressure Determination; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Ramipril; Renin; Renin-Angiotensin System; Spironolactone; Tetrazoles; Young Adult | 2014 |
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypertension; Irbesartan; Male; Prospective Studies; Spironolactone | 2018 |
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Irbesartan; Male; Morbidity; Myocardial Infarction; Risk Factors; Spironolactone; Stroke Volume; Systole; Tetrazoles | 2020 |
11 other study(ies) available for spironolactone and avapro
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, Western; Collagen Type I; Eplerenone; Heart Failure; Hemodynamics; Irbesartan; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Spironolactone; Tetrazoles; Ventricular Remodeling | 2005 |
Aldosterone induction of hepatic stellate cell contraction through activation of RhoA/ROCK-2 signaling pathway.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cell Size; Cells, Cultured; Hepatic Stellate Cells; Irbesartan; Male; Mineralocorticoid Receptor Antagonists; Myosin Light Chains; Pyridines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Spironolactone; Stress Fibers; Tetrazoles | 2011 |
Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.
Topics: Benzimidazoles; Biphenyl Compounds; Female; Fluorobenzenes; Geography; Heart Failure; Humans; Internationality; Irbesartan; Male; Mineralocorticoid Receptor Antagonists; Patients; Pyrimidines; Rosuvastatin Calcium; Spironolactone; Stroke Volume; Sulfonamides; Tetrazoles | 2015 |
Does this patient have hypertensive encephalopathy?
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tomography Angiography; Confusion; Creatinine; Electrocardiography; Glomerular Filtration Rate; Hallucinations; Headache; Heart; Humans; Hydrochlorothiazide; Hypertension; Hypertensive Encephalopathy; Irbesartan; Magnetic Resonance Imaging; Male; Middle Aged; Propanolamines; Renal Artery Obstruction; Spironolactone; Tetrazoles; Ultrasonography | 2016 |
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiac Pacing, Artificial; Cardiovascular Diseases; Cause of Death; Death, Sudden, Cardiac; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mortality; Pacemaker, Artificial; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Spironolactone; Stroke Volume; Tetrazoles; Ventricular Dysfunction, Left | 2019 |
Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma.
Topics: Adsorption; Antihypertensive Agents; Chromatography, High Pressure Liquid; Diltiazem; Furosemide; Humans; Hydrochlorothiazide; Irbesartan; Iron; Labetalol; Limit of Detection; Losartan; Metal Nanoparticles; Methyldopa; Nanocomposites; Polyvinyl Alcohol; Prazosin; Propranolol; Reproducibility of Results; Solid Phase Microextraction; Spironolactone; Valsartan | 2020 |